Tirzepatide Tied to Lower Suicidal Ideation Risk in Obesity and Depression

Adults living with both obesity and major depressive disorder who started tirzepatide showed a lower recorded risk of suicidal ideation than comparable patients who began other anti-obesity medications, according to a retrospective cohort study published in Translational Psychiatry. Using deidentified electronic health records from the TriNetX Global Collaborative Network, researchers compared adults aged 18 and older with diagnosed obesity and major depressive disorder who initiated tirzepatide against matched patients who started non-GLP-1 receptor agonist anti-obesity drugs. After propensity score matching produced 24,103 pairs, tirzepatide use was associated with a 37 percent lower hazard of suicidal ideation, with a hazard ratio of 0.63 and a 95 percent confidence interval of 0.42 to 0.93.

The study was designed as a propensity score-matched cohort analysis, a method that pairs patients receiving tirzepatide with patients receiving comparator anti-obesity medications who share similar baseline characteristics. Matching on observable variables is intended to reduce the imbalances that would otherwise make the two groups difficult to compare, and it produced the 24,103 matched pairs on which all of the reported hazard ratios rest. The primary outcome was suicidal ideation, recorded in the health record data.

The analysis went beyond its primary outcome. Tirzepatide initiation was also associated with reduced hazards of anxiety disorders (HR, 0.83; 95% CI, 0.81 to 0.86), insomnia disorders (HR, 0.92; 95% CI, 0.86 to 0.98), all-cause mortality (HR, 0.38; 95% CI, 0.25 to 0.58), and emergency department visits or hospitalizations (HR, 0.94; 95% CI, 0.89 to 0.99). Each of these estimates carries its own confidence interval, and the mortality estimate, while the largest relative reduction, is also the widest.

Risk reductions were generally consistent across prespecified subgroups, meaning the direction of the association held when the cohort was divided into the patient groups the researchers defined before analysis. The investigators also performed control outcome analyses, a technique used to probe whether residual confounding might explain an observed association, and reported that these analyses supported the internal validity of the findings.

The clinical backdrop gives the result its weight. Obesity and major depressive disorder frequently co-occur and reinforce each other’s risks, including elevated suicidality, yet the psychiatric safety of tirzepatide, a dual GIP and GLP-1 receptor agonist known for its metabolic effects, has remained uncertain in this high-risk population. The authors frame the findings as real-world evidence that tirzepatide may serve as a metabolically favorable treatment option associated with a lower recorded risk of suicidal ideation among adults with comorbid obesity and depression.

That framing comes with an explicit caution from the researchers themselves: the observational association should not be interpreted as evidence of a direct antisuicidal effect. The study measured what was recorded in health records after patients began one medication or another, not what the drugs do biologically to suicidal thinking, and the authors draw the line between the two deliberately.

That caution matters for how the study should be read. As a retrospective analysis of electronic health records rather than a randomized trial, the design can identify associations but cannot establish causation, and unmeasured differences between patients who receive tirzepatide and those who receive other anti-obesity medications may still influence the results. The mortality and psychiatric outcomes rest on recorded diagnoses and encounters within the network, and the reported hazard ratios describe relative risks within this matched cohort rather than guarantees for any individual patient.

Within those limits, the study reports a consistent pattern: lower recorded hazards for suicidal ideation, anxiety, insomnia, all-cause mortality, and acute care use among tirzepatide initiators with comorbid obesity and major depressive disorder, with the direction of association holding across prespecified subgroups and control outcome analyses supporting the internal validity of the estimates. The findings are presented as real-world evidence about recorded outcomes in this vulnerable, high-risk population, with the association between tirzepatide initiation and suicidal ideation remaining observational rather than causal.

Subject of Research: Psychiatric safety of tirzepatide in adults with comorbid obesity and major depressive disorder

Article Title: Association between tirzepatide use and risk of suicidal ideation among individuals with obesity and major depressive disorder

Article References: Liu, T.-H., Chu, C.-C., Liu, C.-Y., Wu, J.-Y., Tsai, Y.-W., Chang, H.-A., & Lai, C.-C. (2026). Association between tirzepatide use and risk of suicidal ideation among individuals with obesity and major depressive disorder. Translational Psychiatry. https://doi.org/10.1038/s41398-026-04518-0

Image Credits: AI Generated

DOI: 10.1038/s41398-026-04518-0

Keywords: tirzepatide, suicidal ideation, obesity, major depressive disorder, GLP-1 receptor agonists, propensity score matching, cohort study, psychiatric safety, TriNetX, real-world evidence, Translational Psychiatry, Association